Axsome Therapeutics is trading 4.2% down at $209.04, mainly amid biotechnology profit-taking and broader risk-off trading.
- No fresh company-specific announcement was identified for August 20, 2026; the latest major update was its August 10 second-quarter report.
- The report showed $218.4 million in revenue, 46% year-over-year growth, and an earnings miss.
- XBI is down 2.47% and the Nasdaq is down 1.00%; rising Treasury yields and weaker equities are pressuring growth-oriented healthcare stocks.